HCW Biologics to Participate in the 2025 Maxim Growth Summit
HCW Biologics (NASDAQ: HCWB) announced it will participate in the 2025 Maxim Growth Summit held October 22–23 at The Hard Rock Hotel NYC.
Founder and CEO Dr. Hing C. Wong will meet one-on-one with institutional investors and senior Maxim analysts; the program includes CEO roundtables and keynote speakers. The company described the event as an opportunity to discuss its clinical-stage immunotherapy programs linking chronic inflammation and disease.
HCW Biologics (NASDAQ: HCWB) ha annunciato che parteciperà al 2025 Maxim Growth Summit, che si terrà dal 22 al 23 ottobre presso l'Hotel Hard Rock di NYC.
Il fondatore e CEO Dr. Hing C. Wong incontrerà investitori istituzionali e analisti senior di Maxim one-to-one; il programma include tavole rotonde con i CEO e relatori principali. L'azienda ha descritto l'evento come un'opportunità per discutere i propri programmi di immunoterapia in fase clinica che collegano l'infiammazione cronica e la malattia.
HCW Biologics (NASDAQ: HCWB) anunció que participará en el Maxim Growth Summit 2025, que se celebrará los días 22 y 23 de octubre en The Hard Rock Hotel NYC.
El fundador y CEO Dr. Hing C. Wong se reunirá cara a cara con inversores institucionales y analistas senior de Maxim; el programa incluye mesas redondas de CEO y ponentes principales. La empresa describió el evento como una oportunidad para discutir sus programas de inmunoterapia en fase clínica que conectan la inflamación crónica y la enfermedad.
HCW Biologics (NASDAQ: HCWB)는 2025 Maxim Growth Summit에 참여할 것이라고 발표했다. 행사는 10월 22일부터 23일까지 뉴욕시의 The Hard Rock Hotel에서 열린다.
창립자이자 CEO Dr. Hing C. Wong은 기관 투자자 및 Maxim의 선임 애널리스트들과 일대일로 만날 예정이며, 프로그램에는 CEO 토론회와 기조 연설자들이 포함된다. 회사는 이 행사를 만성 염증과 질병을 연결하는 임상 단계의 면역 치료 프로그램을 논의할 기회로 설명했다.
HCW Biologics (NASDAQ: HCWB) a annoncé qu'il participera au Maxim Growth Summit 2025, qui se tiendra les 22 et 23 octobre au The Hard Rock Hotel NYC.
Le fondateur et PDG, le Dr Hing C. Wong, rencontrera en tête-à-tête des investisseurs institutionnels et des analystes seniors de Maxim; le programme comprend des tables rondes avec des PDG et des orateurs principaux. L'entreprise a décrit l'événement comme une opportunité de discuter de ses programmes d'immunothérapie en phase clinique liant l'inflammation chronique et la maladie.
HCW Biologics (NASDAQ: HCWB) gab bekannt, dass es am Maxim Growth Summit 2025 teilnehmen wird, der vom 22. bis 23. Oktober im The Hard Rock Hotel NYC stattfindet.
Gründer und CEO Dr. Hing C. Wong wird sich eins zu eins mit institutionellen Investoren und leitenden Maxim-Analysten treffen; das Programm umfasst CEO-Runden Tische und Hauptredner. Das Unternehmen bezeichnete die Veranstaltung als Gelegenheit, seine klinisch fortgeschrittenen Immuntherapie-Programme zu diskutieren, die chronische Entzündungen und Krankheit verbinden.
أعلنت HCW Biologics (بورصة ناسداك: HCWB) أنها ستشارك في قمة Maxim Growth Summit 2025 التي ستعقد في 22-23 أكتوبر في فندق هارد روك نيويورك.
سيجتمع المؤسس والرئيس التنفيذي الدكتور هينغ ك. وانغ وجهاً لوجه مع المستثمرين المؤسسيين والمحللين الكبار في Maxim؛ يتضمن البرنامج جلسات موائد مستديرة للمديرين التنفيذيين والمتحدثين الرئيسيين. وصفت الشركة الحدث بأنه فرصة لمناقشة برامجها للعلاج المناعي في المرحلة السريرية التي تربط الالتهاب المزمن بالمرض.
HCW Biologics (NASDAQ: HCWB) 宣布将参加 2025 Maxim Growth Summit，活动将于 10 月 22 日至 23 日在纽约市 Hard Rock Hotel 举行。
创始人兼首席执行官 Dr. Hing C. Wong 将与机构投资者及 Maxim 的高级分析师进行一对一会面；该项目包括首席执行官圆桌会和主旨发言人。公司将此次活动描述为讨论其处于临床阶段的免疫治疗项目、将慢性炎症与疾病联系起来的机会。
- None.
- None.
MIRAMAR, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, is pleased to announce its participation in the upcoming 2025 Maxim Growth Summit, taking place from October 22nd to 23rd at The Hard Rock Hotel NYC. This prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries.
Dr. Hing C. Wong, the Company’s Founder and Chief Executive Officer, will be meeting with institutional investors in a one-on-one format, and senior Maxim analysts during the event.
Keynote speakers include Larry Kudlow (Broadcaster, Fox News) and Christopher Ruddy (CEO, Newsmax Media). The conference will also feature roundtable discussions with CEOs from small and mid-cap companies, moderated by Maxim Research Analysts. Roundtable discussions will cover a range of sectors, including biotechnology, stem cell therapy, ophthalmology, artificial intelligence, energy and mining, drones, and more.
For more information and a complete agenda of the Maxim Growth Summit, please visit www.maximgrp.com/2025-growth-summit.
About HCW Biologics:
HCW Biologics Inc. (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing proprietary immunotherapies to treat diseases promoted by chronic inflammation, especially age-related and senescence-associated diseases. The Company’s immunotherapeutics represent a new class of drugs that it believes have the potential to fundamentally change the treatment of cancer and many other diseases and conditions that are promoted by chronic inflammation — and in doing so, improve patients’ quality of life and potentially extend longevity. Chronic inflammation, including inflammaging, is believed to be a significant contributing factor to senescence-associated diseases and conditions that diminish healthspan, including many types of cancer, autoimmune diseases, and neurodegenerative diseases, as well as many indications that impact quality-of-life that are not life-threatening. The Company’s lead product candidate, HCW9302, was developed using the Company’s legacy TOBI™ (Tissue factOr-Based fusIon) platform. The Company has created another drug discovery technology, the TRBC platform, which is not based on Tissue Factor. The TRBC platform has the capability to construct immunotherapeutics that not only activate and target immune responses but are also equipped with receptors that specifically target cancerous or infected cells. This platform is a versatile scaffold that enables the creation of multiple classes of immunotherapeutic compounds: Class I: Multi-Functional Immune Cell Stimulators; Class II: Second-Generation Immune Checkpoint Inhibitors; Class III: Multi-Specific Targeting Fusions and Enhanced Immune Cell Engagers. These novel immunotherapeutics are being developed for treatment of a wide range of disease indications, including oncology, autoimmune diseases, and improving quality of life conditions. The Company has constructed over 50 molecules using the TRBC platform. Further preclinical evaluation studies are currently being conducted for these molecules the Company has selected based on promising preclinical data. The Company has two licensing programs in which it has licensed exclusive rights for some of its proprietary molecules. See the Company Pipeline at https://hcwbiologics.com/pipeline/
About Maxim Group LLC
Maxim Group LLC is a full-service investment banking, securities and wealth management firm headquartered in New York. The independent and employee-owned firm provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed-income and derivatives sales & trading, equity research and prime brokerage services. Maxim Group LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission (SEC) and the Municipal Securities Rulemaking Board (MSRB) and is a member of FINRA, SIPC, and NASDAQ. To learn more about Maxim Group LLC, visit maximgrp.com.
Forward Looking Statements:
Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words and include the actual success and potency of the Company’s TRBC platform molecules. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties that are described in the section titled “Risk Factors” in the annual report on Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on March 28, 2025, the latest Form 10-Q filed with the SEC on August 18, 2025 and in other filings filed from time to time with the SEC.
Company Contact:
Rebecca Byam
Chief Financial Officer
HCW Biologics Inc.
RebeccaByam@HCWBiologics.com
FAQ
When will HCW Biologics (HCWB) present at the 2025 Maxim Growth Summit?
Who from HCW Biologics will attend the 2025 Maxim Growth Summit?
Will HCW Biologics hold investor meetings at the Maxim Growth Summit on October 22–23, 2025?
What topics related to HCW Biologics (HCWB) are expected to be discussed at the Maxim Growth Summit?
How can investors find the Maxim Growth Summit agenda referenced by HCW Biologics?
Does HCW Biologics announce any new financial guidance or clinical readouts tied to the Maxim Growth Summit?
